Influenza Vaccines
Research News and Information

Monday, November 23, 2009

Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009.

11 Nov 2009 Since first reports in April 2009, the 2009 pandemic influenza A (H1N1) virus has spread around the world. The pandemic virus is antigenically distinct from seasonal influenza A (H1N1) viruses targeted by seasonal influenza vaccines. Results from ... Read more...

Update on influenza A (H1N1) 2009 monovalent vaccines.

7 Oct 2009 On September 15, 2009, four influenza vaccine manufacturers received approval from the Food and Drug Administration for use of influenza A (H1N1) 2009 monovalent influenza vaccines in the prevention of influenza caused by the 2009 pandemic influenza ... Read more...

Influenza vaccination coverage among children and adults - United States, 2008-09 influenza season.

7 Oct 2009 Before 2008, the Advisory Committee on Immunization Practices (ACIP) had recommended annual vaccination for influenza for persons aged >or=50 years, 18-49 years at higher risk for influenza complications, and 6 months--4 years. In 2008, ACIP ... Read more...

Latest indexed articles for 'Influenza Vaccines'

These are the very latest articles for this heading:

• Avoiding Guillan-Barré Syndrome following swine origin pandemic H1N1 2009 influenza vaccination. 13 Nov 2009
• Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. 11 Nov 2009
• H1N1 vaccine urged for health workers, but some resist getting on board. 2 Nov 2009
• CDC updates recommendations for protecting clinicians from influenza. 2 Nov 2009
• Influenza vaccine market dynamics. 30 Oct 2009
• Lessons learned. 30 Oct 2009
• Only 12% of Germans say they will have H1N1 vaccine after row blows up over safety of adjuvants. 19 Oct 2009
• H1N1 vaccination begins as proportion of cases in hospital admitted to intensive care rises. 17 Oct 2009
• [Dangerous adjuvant in swine influenza vaccine] 17 Oct 2009
• Virology. In Holland, the public face of flu takes a hit. 14 Oct 2009
• Four H1N1 vaccines demonstrate safety and effectiveness, receive FDA approval. 13 Oct 2009
• WHO will start delivering H1N1 vaccine to 100 poorer nations in November. 12 Oct 2009
• The H1N1 vaccine plan. 11 Oct 2009
• CMA on the vaccine plan. 11 Oct 2009
• Antigenic and genetic characteristics of influenza A(H5N1) viruses and candidate vaccine viruses developed for potential use in human vaccines. 7 Oct 2009
• Recommended composition of influenza virus vaccines for use in the 2010 influenza season (southern hemisphere winter). 7 Oct 2009
• Update on influenza A (H1N1) 2009 monovalent vaccines. 7 Oct 2009
• Influenza vaccination coverage among children and adults - United States, 2008-09 influenza season. 7 Oct 2009
• How to win trust over flu. 6 Oct 2009
• The future of influenza vaccines. 4 Oct 2009

See a longer list of these articles.

Technical information about 'Influenza Vaccines'

Definition: Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed or attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.

Registry Number: 0

Descriptor UI: D007252

Alternative terms: Influenza Vaccines; Vaccines, Influenza; Influenzavirus Vaccines; Vaccines, Influenzavirus; Influenza Virus Vaccines; Vaccines, Influenza Virus; Virus Vaccines, Influenza; Flu Vaccines; Vaccines, Flu; Influenza Vaccine; Vaccine, Influenza; Trivalent Live Attenuated Influenza Vaccine; LAIV vaccine; vaccine, LAIV; FluMist; MedImmune Vaccines Brand of Trivalent Live Attenuated Influenza Vaccine; CAIV-T vaccine;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D20.215.894.899.302;

History Note: 2005 (1963)

Technical Notes: coordinate IM with specific influenza virus or virus subtype /immunol (IM); SCR records for several specific influenza vaccines are also available; not for Haemophilus influenzae vaccines ( = HAEMOPHILUS VACCINES)